Proteasome inhibitors bind to the proteasome and prevent degradation of proteins involved in various signaling cascades. Preclinical studies in AML indicate proteasome inhibition disrupts proliferative cell signaling pathways, has cytotoxic synergism with other chemotherapies, and induces autophagy. For example, in AML, bortezomib is being investigated with combination chemotherapy regimens.